Voriconazole

Red

Brand Name(s):Vfend

Indication:Invasive aspergillosis, serious infections caused by Scedosporium spp, Fusarium sp or invasive fluconazole resistant Candida spp

Rationale:1,2

Considered:Jan-07

Review Date:Jul-24

Comments:
MHRA Guidance for further information go to; http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON418519

Voriconazole (Vfend) is known to be associated with a risk of liver toxicity, phototoxicity, and squamous cell carcinoma of the skin. Test liver function before starting treatment with voriconazole and at least weekly during the first month of treatment. Tell patients to avoid sunlight exposure while taking voriconazole. New tools to help monitor and manage these risks are being distributed

May 2014